- Home
- ILLR vs ADVM Comparison
ILLR vs ADVM Comparison
Compare ILLR & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ADVM
- Stock Information
- Founded
- ILLR 2015
- ADVM 2006
- Country
- ILLR United States
- ADVM United States
- Employees
- ILLR N/A
- ADVM N/A
- Industry
- ILLR Investment Managers
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ILLR Finance
- ADVM Health Care
- Exchange
- ILLR Nasdaq
- ADVM Nasdaq
- Market Cap
- ILLR 79.7M
- ADVM 66.3M
- IPO Year
- ILLR N/A
- ADVM 2014
- Fundamental
- Price
- ILLR $0.69
- ADVM $3.02
- Analyst Decision
- ILLR
- ADVM Strong Buy
- Analyst Count
- ILLR 0
- ADVM 4
- Target Price
- ILLR N/A
- ADVM $19.75
- AVG Volume (30 Days)
- ILLR 3.8M
- ADVM 84.1K
- Earning Date
- ILLR 11-13-2025
- ADVM 11-03-2025
- Dividend Yield
- ILLR N/A
- ADVM N/A
- EPS Growth
- ILLR N/A
- ADVM N/A
- EPS
- ILLR N/A
- ADVM N/A
- Revenue
- ILLR $45,244,000.00
- ADVM $1,000,000.00
- Revenue This Year
- ILLR N/A
- ADVM $1,836.70
- Revenue Next Year
- ILLR N/A
- ADVM N/A
- P/E Ratio
- ILLR N/A
- ADVM N/A
- Revenue Growth
- ILLR N/A
- ADVM N/A
- 52 Week Low
- ILLR $0.40
- ADVM $1.78
- 52 Week High
- ILLR $6.52
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- ILLR 62.81
- ADVM 50.02
- Support Level
- ILLR $0.41
- ADVM $2.93
- Resistance Level
- ILLR $0.76
- ADVM $3.59
- Average True Range (ATR)
- ILLR 0.09
- ADVM 0.22
- MACD
- ILLR 0.03
- ADVM -0.02
- Stochastic Oscillator
- ILLR 70.08
- ADVM 13.64
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.